Rational prescribing of anti-epilepsy drugs in children may be complicated by a number of problems, which include: (i) difficulties in arriving rapidly at a syndromic diagnosis, at least in some cases, with consequent uncertainties about therapeutic management; (ii) difficulties in evaluating drug response in young age groups, particularly with respect to subjective side-effects affecting cognitive function; (iii) the vulnerability of infants and children to specific aspects of drug toxicity, such as liver damage induced by valproic acid or behavioural disorders caused by barbiturates; and {iv) the need to adjust dosage to account for age-dependent pharmacokinetic changes. In particular, it is known that the rate of drug metabolism changes markedly during development. Metabolic drug elimination is often reduced at birth, but drug metabolizing enzymes mature rapidly and biotransformation in infants and children usually occurs at a faster rate than in adults. The elimination of drugs which are excreted unchanged in urine appears to be less influenced by age in paediatric patients, though impairment in renal drug clearance may be seen in newborns. Monitoring of serum drug concentrations may be helpful for dosage adjustments, but it is not a substitute for careful clinical observation.
INTRODUCTION
In most cases, epilepsy has its onset in infancy and childhood. Although some syndromic forms (most notably the idiopathic partial epilepsies) may not always require drug treatment, the vast majority of children need appropriate pharmacological therapy to prevent recurring seizures.
The drug treatment of epilepsy in infancy and childhood is associated with specific problems which may not be encountered in an adult population. These problems encompass a wide range of diagnostic, therapeutic and pharmacokinetic aspects which need to be taken into consideration for rational drug selection and the individualization of dose.
DIAGNOSTIC CONSIDERATIONS
Adequate therapeutic management is critically dependent on the physician's ability to make a correct diagnosis. Many epileptic syndromes of infancy and childhood may not be easily diagnosed at their onset, and a misclassification of seizure type or syndromic form may lead to inappropriate treatment. For example, carbamazepine may be ineffective and even worsen myoclonus and absences in adolescents with juvenile myoclonic epilepsy. Unfortunately, it is not always possible to exclude this syndrome in a teenager who presents with only one or two tonic-clonic seizures, because absences and myoclonus may appear later, sometimes after starting carbamazepine therapy 1.
DIFFICULTIES IN EVALUATING DRUG RESPONSES
For obvious reasons, the recognition of subjective adverse effects of drug treatment may be particularly difficult in infants and young children. Careful observation by the physician, parents and teachers is required to unmask subtle but potentially important detrimental effects on mood, performance and behaviour. Barbiturates are particularly prone to adversely affect cognitive function and behaviour 2-4, but adverse central nervous system effects may also be encountered to a lesser extent with other drugs.
AGE-RELATED CHANGES IN DRUG RESPONSIVENESS
The adverse effect profile of many anti-epilepsy drugs differs in children and adults (Table 1) . For example, newborn babies of mothers treated with anti-epilepsy drugs (particularly phenytoin and barbiturates) are at risk of developing a potentially fatal coagulation disorder unless prophylactic treatment with vitamin K is given to the baby at birth, or to the mother during late pregnancy 5. Surprisingly, anti-epilepsy drugs do not appear to cause such coagulation disorders in adult patients. 
AGE-RELATED DIFFERENCES IN PHARMACOKINETICS
The possibility of achieving optimal seizure control depends not only on choosing the correct agent, but also on identifying the best dose to fulfil individual needs. This is most important in children because dose requirements may vary with time due to increasing body weight and pharmacokinetic changes that occur during development. Hence, an understanding of the clinical pharmacokinetics of antiepilepsy drugs in infants and children is essential for rational prescribing.
Absorption
The gastrointestinal absorption of many drugs is erratic in neonates but rapidly becomes more efficient during postnatal development. In infants and children, the oral bioavailability of anticonvulsants is similar to that observed in adults 6. It should be remembered, however, that the rate of drug absorption is often enhanced after intake of liquid formulations, which are often used in children.
A parenteral route may be indicated when a rapid effect is required (as with intravenous diazepam to treat status epilepticus), when a child is unable to take the medicine orally, or when gastrointestinal absorption is inefficient, such as with phenobarbitone in the newborn. For many drugs, such as diazepam and phenytoin, absorption from intramuscular sites tends to be slow and erratic. Rectal administration of diazepam in solution produces serum drug levels above the anticonvulsant threshold within a few minutes v.
Another example of altered drug responsiveness in paediatric patients is represented by the high incidence of irritability, hyperkinesia and other behavioural disturbances in infants and children treated with barbiturates and benzodiazepines. Similarly, children aged 2 years or younger are known to be at much greater risk of developing valproate-induced liver damage.
Certain adverse effects of anti-epilepsy drugs may occur at any age but acquire special relevance in childhood. For example, phenytoin-induced hirsutism and gum hyperplasia has greater psychosocial implications in a young girl than in an elderly male.
Distribution
The plasma protein binding of phenytoin, phenobarbitone and valproic acid may be reduced in the neonate, particularly in those born prematurely. Since only the free, non-proteinbound drug is pharmacologically active, this phenomenon must be taken into account when interpreting serum drug concentrations in clinical practice. In fact, because of the increase in free fraction, the total (free plus protein-bound) drug concentration required for an optimal response may be lower in newborn than older patients 6. This is particularly true for drugs such as phenytoin and valproic acid, Half-life refers to active metabolite 10-hydroxycarbazepine. § Phenytoin half-life increases with increasing serum concentrations of the drug l in children, from about 10 hours at low concentrations to about 20 hours at therapeutic concentrationsl. Elimination is faster in children than in adults. NE Usefulness of serum level monitoring has not been established.
which are more extensively bound to plasma proteins.
Elimination
The elimination half-life of most anticonvulsants is prolonged in neonates as a result of immaturity of the drug metabolizing enzymes and/or renal excretion mechanisms (Table 2 ). In the case of enzyme-inducing drugs Ibarbiturates, phenytoin, carbamazepine), transplacental induction may occur and metabolic drug elimination may be more efficient in neonates exposed to the drug in utero compared to nonexposed neonates 9.
The activity of the drug metabolizing enzymes increases rapidly during postnatal development and, within a few weeks or months, reaches levels generally higher than in adults (Table 2 ). To compensate for the increased elimination, older infants and children usually require maintenance doses which are considerably higher (when expressed as mg/kg) than those used in adults 1°. Moreover, for drugs such as carbamazepine and phenytoin, the shorter elimination half-lives in paediatric patients imply that more frequent daily administration is required to minimize fluctuations in drug serum levels between doses. Since metabolic changes occur at different ages in different patients, the degree of pharmacokinetic variation tends to be greater in children than in adults, and individualization of dose may be particularly difficult. Moreover, because of the age-related metabolic changes, dose adjustments in the same patient cannot be based simply on the increase in body weight. Careful monitoring of clinical response, sometimes aided by serum drug level measurements, is required to determine the need for dose modification.
In general, the elimination of drugs which are excreted unchanged in urine {for example, vigabatrin} appears to be less influenced by age ° changes in paediatric patients. An impairment in renal drug clearance, however, may be expected in neonates, especially in those born prematurely.
ANTI-EPILEPSY DRUG INTERACTIONS
Although most children with epilepsy can be treated satisfactorily with a single drug, some patients require combination therapy and are therefore at risk of potentially adverse drug interactions. Interactions may also occur with drugs used for unrelated medical conditions.
Pharmacokinetic drug interactions
These interactions may affect absorption, distribution or elimination processes (Table 3}. The interaction between phenytoin and val- Phenytoin is displaced from plasma protein binding sites. Total serum phenytoin levels underestimate the level of free, pharmacologically active drug. Serum carbamazepine levels are reduced due to enzyme induction. Carbamazepine dose requirements may increase. Serum levels of affected drug may decrease due to enzyme induction. Dose requirements may increase accordingly. Serum phenytoin levels may decrease. Serum phenobarbitone levels may increase due to metabolic inhibition with attendant risk of intoxication. Serum phenobarbitone and lamotrigine levels increase due to metabolic inhibition, with attendant risk of intoxication. Serum levels of the active metabolite carbamazepine-10,11-epoxide increase markedly and may precipitate signs of intoxication. Serum levels of affected drug may decrease due to enzyme induction. Dosage requirements may increase accordingly.
Serum concentrations of affected drug may increase due to metabolic inhibition, with attendant risk of intoxication.
proic acid is a good example of the events which occur when there is drug displacement from plasma protein binding sites. The displaced drug (phenytoin) undergoes rapid elimination and redistribution into the tissues, resulting in decreased total serum concentrations. The concentration of free, pharmacologically active drug is, however, unaltered or may be even slightly increased. This interaction does not usually affect clinical response, but should be taken into account when interpreting serum phenytoin levels in clinical practice. In fact, total serum phenytoin measurements in valproate-treated patients underestimate the level of free, pharmacologically active drug and, despite the fall in total drug levels, the phenytoin dose does not need to be increased.
Metabolic interactions may involve either induction or inhibition of biotransformation processes. The increased elimination of valproic acid, lamotrigine, theophylline and prednisolone in patients treated concurrently with carbamazepine, phenytoin or barbiturates provide good examples of clinically significant enzyme induction. Conversely, the rise in serum concentration of lamotrigine or phenobarbitone in patients treated with valproic acid, or the precipitation of carbamazepine intoxication by erythromycin, are important examples of metabolic inhibitory interactions (Table 3) .
Renally eliminated drugs such as gabapentin and vigabatrin are much less liable to be involved in drug interactions. However, a decrease in serum phenytoin concentration after addition of vigabatrin has been described.
Pharmacodynamic drug interactions
Pharmacodynamic interactions may result in synergism or antagonism at the site of action. These interactions generally have adverse clinical consequences, the best example being represented by the possible development of drug intoxication in children receiving a combination of several anticonvulsants, despite low doses and low serum concentrations of the individual agents. Favourable pharmacodynamic interactions have also been reported. The best documented example involves valproic acid and ethosuximide, whose combination may prove remarkably effective in patients with absence seizures refractory to either drug given alone 13.
CONCLUSION
Rational therapy of epilepsy in children requires a good knowledge of the clinical pharmacology of the various anticonvulsants. In particular, drug selection should take into consideration not only the spectrum of efficacy, but also the toxicity profile of individual agents. Children differ from adults in dosage requirements and in susceptibility to particular aspects of drug toxicity, and careful monitoring of clinical response is required to ensure optimal seizure suppression without excessive adverse effects.
